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Reply: An Incomplete Story 
 
We thank Dr. Reiffel for his interest in our paper (1). Beta-blockers reduced 
mortality in landmark, placebo-controlled trials of heart failure with a reduced left 
ventricular ejection fraction only for those in sinus rhythm rather than atrial 
fibrillation (AF), despite use of similar beta-blocker formulations and doses (84% 
of target) and similar heart rate reductions (1). For patients in AF, neither 
baseline nor follow-up ventricular rate was associated with beta-blocker benefit, 
nor have trials comparing rate control intensity shown important differences in 
outcome, although slower rates may be associated with a worse prognosis for 
patients with heart failure (2). 
 
Physiologically, slowing heart rate increases pulse and systolic blood pressures. 
Multivariable analyses investigating interactions amongst heart rate, rhythm, 
and beta-blockers were adjusted for systolic pressure. AF with ventricular rate 
<70 beats/min was associated with a 6 mm Hg higher systolic pressure than 
when >90 beats/min but higher pressure was not associated with a better 
prognosis. 
 
Data on individual angiotensin-converting-enzyme inhibitors or angiotensin-
receptor blockers or their doses were not collected but the proportion prescribed 
(about 95%) these was similar regardless of heart rhythm. Analyses correcting 
for use of mineralocorticoid antagonists and digoxin did not affect our 
conclusions (see Online Table 3 in [1]). 
 
Observational studies of digoxin are prone to prescribing and other biases, even 
when propensity-adjusted, and should not be used to assess treatment 
responses. Randomized trials show no impact of digoxin on mortality in sinus 
rhythm but do show reductions in hospitalization (3). Prospective trials of 
cardiac glycosides in patients with AF are underway (4). 
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